If approved, asciminib would beef up Novartis' CML portfolio, which is a big earner for the company. Tasigna made sales of $1.8 billion last year, and despite generics Glivec is still a ...

CML Unlocks AI’s Full Potential with Enhanced Pattern Recognition, Prediction, and Real-Time Decision-Making for Defense, Autonomous Systems, and Next-Gen Computing Infleqtion, a global leader ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.